Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
    • COVID-19 Content and Resources
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Other Publications
    • ajnr

User menu

  • Subscribe
  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

  • Subscribe
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
    • COVID-19 Content and Resources
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds
Research ArticlePharmacology Vignette

Natalizumab (Tysabri)

D.T. Selewski, G.V. Shah, B.M. Segal, P.A. Rajdev and S.K. Mukherji
American Journal of Neuroradiology October 2010, 31 (9) 1588-1590; DOI: https://doi.org/10.3174/ajnr.A2226
D.T. Selewski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G.V. Shah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B.M. Segal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
P.A. Rajdev
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S.K. Mukherji
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

References

  1. 1.↵
    1. Rudick RA,
    2. Stuart WH,
    3. Calabresi PA,
    4. et al
    . Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911– 23
    CrossRefPubMedWeb of Science
  2. 2.↵
    1. Polman CH,
    2. O'Connor PW,
    3. Havrdova,
    4. et al
    . A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899– 910
    CrossRefPubMedWeb of Science
  3. 3.↵
    1. Gordon FH,
    2. Lai CW,
    3. Hamilton MI,
    4. et al
    . A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001; 121: 268– 74
    CrossRefPubMed
  4. 4.↵
    1. Ghosh S,
    2. Goldin E,
    3. Gordon FH,
    4. et al
    . Natalizumab for active Crohn's disease. N Engl J Med 2003; 348: 24– 32
    CrossRefPubMedWeb of Science
  5. 5.↵
    1. Sandborn WJ,
    2. Colombel JF,
    3. Enns R,
    4. et al
    . Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912– 25
    CrossRefPubMedWeb of Science
  6. 6.↵
    Department of Health and Human Services. Tysabri risk minimization action plan: summary of TOUCH. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM107197.pdf. Accessed June 28, 2010
  7. 7.↵
    1. Lobb RR,
    2. Hemler ME
    . The pathophysiologic role of alpha 4 integrins in vivo. J Clin Invest 1994; 94: 1722– 28
    PubMedWeb of Science
  8. 8.↵
    1. Yednock TA,
    2. Cannon C,
    3. Fritz LC,
    4. et al
    . Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63– 66
    CrossRefPubMed
  9. 9.↵
    1. Brocke S,
    2. Piercy C,
    3. Steinman L,
    4. et al
    . Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc Natl Acad Sci U S A 1999; 96: 6896– 901
    Abstract/FREE Full Text
  10. 10.↵
    1. Rice GP,
    2. Hartung HP,
    3. Calabresi PA
    . Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005; 64: 1336– 42
    Abstract/FREE Full Text
  11. 11.↵
    1. Ley K,
    2. Laudanna C,
    3. Cybulsky MI,
    4. et al
    . Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 2007; 7: 678– 89
    CrossRefPubMedWeb of Science
  12. 12.↵
    1. Goodin DS,
    2. Cohen BA,
    3. O'Connor P,
    4. et al
    . Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 71: 766– 73
    Abstract/FREE Full Text
  13. 13.↵
    1. Rudick RA,
    2. Sandrock A
    . Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother 2004; 4: 571– 80
    CrossRefPubMed
  14. 14.↵
    1. Miller DH,
    2. Khan OA,
    3. Sheremata WA,
    4. et al
    . A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15– 23
    CrossRefPubMedWeb of Science
  15. 15.↵
    1. Clifford DB,
    2. DeLuca A,
    3. Simpson DM,
    4. et al
    . Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9: 438– 46
    CrossRefPubMedWeb of Science
  16. 16.↵
    1. Bezabeh S,
    2. Flowers CM,
    3. Kortepeter C,
    4. et al
    . Review article: clinically significant liver injury in patients treated with natalizumab (TYSABRI). Aliment Pharmacol Ther 2010; 31: 1028– 35. Epub 2010 Feb 16
    PubMed
  17. 17.↵
    Center for Drug Evaluation and Research (CDER). Tysabri (Natalizumab) biologic license application 125104/15. In: Proceedings of the Peripheral and Central Nervous System Drugs Advisory Committee, Gaithersburg, Maryland. 3 7–8, 2006; available at http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4208S1-Slide-Index.htm. Accessed June 28, 2010
  18. 18.↵
    1. Ismail A,
    2. Kemp J,
    3. Sharrack B
    . Melanoma complicating treatment with natalizumab (Tysabri) for multiple sclerosis. J Neurol 2009; 256: 1771– 72. Epub 2009 Jul 16
    CrossRefPubMedWeb of Science
  19. 19.↵
    1. Mullen JT,
    2. Vartanian TK,
    3. Atkins MB
    . Melanoma complicating treatment with natalizumab for multiple sclerosis. N Engl J Med 2008; 358: 647– 48
    CrossRefPubMedWeb of Science
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 31 (9)
American Journal of Neuroradiology
Vol. 31, Issue 9
1 Oct 2010
  • Table of Contents
  • Index by author
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Natalizumab (Tysabri)
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Natalizumab (Tysabri)
D.T. Selewski, G.V. Shah, B.M. Segal, P.A. Rajdev, S.K. Mukherji
American Journal of Neuroradiology Oct 2010, 31 (9) 1588-1590; DOI: 10.3174/ajnr.A2226

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Natalizumab (Tysabri)
D.T. Selewski, G.V. Shah, B.M. Segal, P.A. Rajdev, S.K. Mukherji
American Journal of Neuroradiology Oct 2010, 31 (9) 1588-1590; DOI: 10.3174/ajnr.A2226
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • Abstract
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Encephalitogenic and Regulatory CD8 T Cells in Multiple Sclerosis and Its Animal Models
  • Crossref
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

More in this TOC Section

  • Dabigatran (Pradaxa)
  • Clopidogrel (Plavix)
  • Trastuzumab (Herceptin)
Show more Pharmacology Vignette

Similar Articles

Advertisement

News and Updates

  • Lucien Levy Best Research Article Award
  • Thanks to our 2022 Distinguished Reviewers
  • Press Releases

Resources

  • Evidence-Based Medicine Level Guide
  • How to Participate in a Tweet Chat
  • AJNR Podcast Archive
  • Ideas for Publicizing Your Research
  • Librarian Resources
  • Terms and Conditions

Opportunities

  • Share Your Art in Perspectives
  • Get Peer Review Credit from Publons
  • Moderate a Tweet Chat

American Society of Neuroradiology

  • Neurographics
  • ASNR Annual Meeting
  • Fellowship Portal
  • Position Statements

© 2023 by the American Society of Neuroradiology | Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire